Total : 72 View more »
The last 75 days have been transformative for BioSante, Bill Milling, Sr. Dir Operations for BioSante Pharmaceuticals, Inc. (BPAX) told <a
http://seekingalpha.com/article/167782-transformative-times-for-biosante-pharmaceuticals?source=feed
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX - News) today announced that it has received commitments from three institutional investors
http://finance.yahoo.com/news/BioSante-Pharmaceuticals-to-bw-1177785347.html?x=0&.v=1
Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX - News) today announced the closing of the sale, directly to three
http://finance.yahoo.com/news/BioSante-Pharmaceuticals-bw-1483659738.html?x=0&.v=1
Total : 41 View more »
Nov 02, 2009 (Wall Street Horizon via COMTEX) --
BioSante Pharmaceuticals Inc. (BPAX)
Expected next earnings release: Announcement date: 11/9/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: corporate earnings market pharmaceuticals
Companies: BioSante Pharmaceuticals, Inc. (BPAX)
Nov 03, 2009 (Wall Street Horizon via COMTEX) --
BioSante Pharmaceuticals Inc. (BPAX)
Expected next earnings release: Announcement date: 11/9/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: corporate earnings market pharmaceuticals
Companies: BioSante Pharmaceuticals, Inc. (BPAX)
LINCOLNSHIRE, Ill., Oct 29, 2009 (BUSINESS WIRE) --
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO, will present an overview of the company and its recently completed acquisition of Cell Genesys, as well as give a LibiGel(R) (testosterone gel) update at the Oppenheimer 20th Annual Healthcare Conference to be held on November 3-4, 2009 at the Waldorf-Astoria in New York City. Mr. Simes will present on November 3, 2009 at 1:00 pm local time.
A live audio webcast of BioSante's presentation at the conference may be accessed at Oppenheimer Health Care Conference. A replay of the presentation will be available at the same link.
About the Oppenheimer Health Care Conference
This Oppenheimer Annual Healthcare Conference will present a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries. Over 19 years, the Oppenheimer Healthcare Conference has become a highly valuable investor conference in this sector. Through formal company presentations and panels, attendees will gain insight from, and access to, industry leaders. The companies participating in this conference will address topical issues such as health reform, Medicare and Medicaid, generic drug regulation, development of new blockbuster pharmaceutical and biotechnology products, product safety and patent issues, cross-border reimportation, Food and Drug Administration policy, managed care, and the current M&A environment.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel(R) (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook(TM)), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, which BioSante acquired from Cell Genesys, Inc. and are non patient-specific therapies comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety and are administered via intradermal injections on an outpatient basis. Additional information is available online at: www.biosantepharma.com.
SOURCE: BioSante Pharmaceuticals, Inc.
Alan Zachary, McKinney/Chicago (312) 944-6784 ext. 316 azachary@mckinneychicago.com For information about participating in the LibiGel clinical studies call or visit the following: 877-BLOOM81; www.bloomstudy.com
Tags: acquisition biotechnology cancer ceo clinical conference contraception environment fda health healthcare local market medical medicine menopause nasdaq new_york online patent pharmaceuticals policy president products swine technology vaccine
Companies: BioSante Pharmaceuticals, Inc. (BPAX), Cell Genesys, Inc. (CEGE)
Oct 28, 2009 (Wall Street Horizon via COMTEX) --
BioSante Pharmaceuticals Inc. (BPAX)
Expected next earnings release: Announcement date: 11/9/2009 - After Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: corporate earnings market pharmaceuticals
Companies: BioSante Pharmaceuticals, Inc. (BPAX)
Total : 24 View more »
If you have an account with NewsRx and have purchased either a NewsRx Bundled package or a NewsRx Pass, you can log into your account below to access this article.
1/7/2004 9:39:58 PM BioSante Pharmaceuticals Announces DynPort Subcontract to Develop Anthrax Vaccines Using Nanotechnology-Based Alternative Delivery Systems
Copyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.
http://www.newratings.com/headlines/BioSante-Pharmaceuticals_US09065V2034.html
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Sept. 13, 2005--BioSante Pharmaceuticals (AMEX:BPA) today announced that Stephen M. Simes, president and chief executive officer, will present a corporate overview at Wall Street Reporter magazine's sixth annual Small-Cap Discovery Conference.
http://www.pharmacychoice.com/News/article.cfm?Article_ID=12641
Total : 73 View more »
Stay informed on the latest Biosante Pharmaceuticals Incorporated news. TheStreet is the source for financial market and Wall Street news, trading stock and personal finance advice
http://www.thestreet.com/topic/5998/biosante-pharmaceuticals-incorporated.html
Information about BioSante Pharmaceuticals Incorporated ... RSS feeds allow Web site content to be gathered via feed reader software.
Find business news, business blogs, executive career advice, business travel, business culture, company & executive profiles.
http://www.portfolio.com/resources/company-profiles/Biosante-Pharmaceuticals-Incorporated-5645
Get the latest BPAX - Biosante Pharmaceuticals Incorporated stock market performance data. TheStreet is the source for financial market news, trading stock, quotes, and personal ...